Oligonucleotide therapeutics have emerged as a promising alternative to traditional small-molecule and protein-based drugs. This Perspective discusses how chemical engineering can broaden oligonucleotide applications to extrahepatic diseases and enable larger-scale production, ultimately allowing treatment of more prevalent conditions than is currently possible.
- Sasha B. Ebrahimi
- Himanshu Bhattacharjee
- Devleena Samanta
